Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14

5 octobre 2017

12:00
COLD SPRING HARBOR, N.Y., Oct. 5, 2017 /PRNewswire/ -- Neuroscientists at Cold Spring Harbor Laboratory (CSHL) have mobilized advanced imaging and computational methods to comprehensively map ? "count" ? the total populations of specific types of...

09:00
MANASSAS, Va., Oct. 5, 2017 /PRNewswire/ -- Notal Vision, Inc., a pioneer in home-based ophthalmic disease monitoring, announced the completion of the three millionth home test performed with ForeseeHome®, the first FDA-cleared home monitoring device...

09:00
FALLS CHURCH, Va., Oct. 5, 2017 /PRNewswire-USNewswire/ -- Inova Schar Cancer Institute announced today it is recruiting patients for the American Society of Clinical Oncology's (ASCO) first-ever clinical trial, the Targeted Agent and Profiling...

08:03
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Oct. 5, 2017 /PRNewswire-USNewswire/ -- A new in-depth retrospective study and related white paper published in late September demonstrate the safe and effective use of ReWalk systems by individuals with...

08:01
OSAKA, Japan and FLORHAM PARK, N.J., Oct. 5, 2017 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi") today announced it will report results of a S-033188 Phase 3 study in otherwise healthy influenza patients (CAPSTONE-1) at IDWeektm 2017,...

08:00
WASHINGTON, Oct. 5, 2017 /PRNewswire-USNewswire/ -- The Prostate Cancer Foundation (PCF) today announced awards totaling $7.5 million to fund new 2017 PCF Challenge Awards supporting international, cross-disciplinary teams of investigators conducting...

08:00
TEL AVIV, Israel, Oct. 5, 2017 /PRNewswire/ -- Galmed Pharmaceuticals, Inc. (GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and...

08:00
GAITHERSBURG, Md., Oct. 5, 2017 /PRNewswire/ -- LKC Technologies is announcing that the revolutionary RETeval device's latest software release (2.8.0) includes age-adjusted normative data, which is available for human use. The reference intervals...

08:00
NEW YORK, Oct. 5, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced a private placement of convertible...

07:00
WALTHAM, Mass., Oct. 5, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced...

07:00
SAN DIEGO, Oct. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA® (valbenazine) capsule strength to be used for the treatment of adults...

04:35
MADRID, October 5, 2017 /PRNewswire/ -- À la fin de l'année 2016, Pharma Mar S.A. avait sollicité l'autorisation de commercialiser le produit dans l'Union européenne La procédure de régularisation de médicaments oncologiques en Suisse est...


4 octobre 2017

16:30
- Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development - VANCOUVER, Oct. 4, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing...

15:20
OSAKA, Japan and FLORHAM PARK, N.J., Oct. 4, 2017 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi") will present clinical trial efficacy results, as well as supportive in vitro data, on cefiderocol (S-649266), an investigational siderophore...

15:00
BOSTON, Oct. 4, 2017 /PRNewswire-USNewswire/ -- In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) ? a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis ? effectively...

14:25
SAN CLEMENTE, Calif., Oct. 4, 2017 /PRNewswire/ -- ROX Medical, Inc., a privately held medical device company pioneering an innovative interventional vascular therapy for Uncontrolled Hypertension, announced today that the first patient was treated...

11:00
MOSCOW, October 4, 2017 /PRNewswire/ -- Hepatera LLC and its development partner MYR GmbH today announced the completion of the 24 weeks active treatment phase in MYR 202 clinical trial, a Phase 2b study investigating Myrcudex B in chronic hepatitis...

09:00
CARLSBAD, California, Oct. 4, 2017 /PRNewswire/ -- Applied Spectral Imaging (ASI), a global leader in computer-assisted biomedical imaging, announced today the launch of PathFusiontm and HiPath Protm, innovative Brightfield and FISH imaging &...

09:00
YOKNEAM, Israel, October 4, 2017 /PRNewswire/ -- GI innovator Vibrant Ltd. has successfully completed two clinical studies in the US and Israel, to test the efficacy and safety of an innovative intraluminal vibrating capsule for treating chronic...

09:00
DURHAM, N.C., Oct. 4, 2017 /PRNewswire/ -- Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with BIOC51, a nitric...

08:30
MADRID, October 4, 2017 /PRNewswire/ -- Pharma Mar S.A. submitted the Marketing Authorisation Application in the European Union at the end of 2016 The regulatory process for oncological products in Switzerland is independent from the European...

08:28
ZURICH, October 4, 2017 /PRNewswire/ -- Sequana Medical AG (Sequana Medical), une société d'instruments médicaux au stade commercial qui innove dans la gestion des maladies hépatiques, annonce la publication de l'article « Traitement des ascites...

08:01
ROSEVILLE, Minn., Oct. 4, 2017 /PRNewswire/ -- Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that three posters highlighting RBX2660 clinical...

08:00
SAN DIEGO, Oct. 4, 2017 /PRNewswire/ -- Zavante Therapeutics, Inc., a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients, is presenting at ID Week 2017 additional data from the company's...

08:00
SAN FRANCISCO, Oct. 4, 2017 /PRNewswire/ -- Adynxx, a clinical stage biotechnology company developing a novel platform of first-in-class, non-opioid, disease-modifying pain therapeutics announced today completion of enrollment in a Phase 2 study of...

08:00
LOS GATOS, Calif., Oct. 4, 2017 /PRNewswire/ -- Thync Global Inc., a bioelectronics company, today reported positive results from a pilot study evaluating the use of its proprietary neuromodulation technology to treat psoriasis. The study showed that...

07:05
SAN DIEGO, Oct. 4, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive...

07:00
SAINT MALO, France, Oct. 4, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its presentation today at the 22nd Annual International Congress of the World Muscle Society, reported that teens and young men in the advanced stages of...

07:00
MONTREAL, Oct. 4, 2017 /PRNewswire/ -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced 48-week efficacy and safety results for ibalizumab in patients infected with multidrug resistant HIV-1 who completed the 24-week Phase III...

06:00
SAN RAMON, Calif., and PITTSBURGH, Pa., Oct. 4, 2017 /PRNewswire/ -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced enrollment of the first patient in the U.S. arm of...

05:30
BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 4, 2017 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking...

04:00
ZURICH, October 4, 2017 /PRNewswire/ -- Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of "Treatment of refractory ascites with an...


3 octobre 2017

16:15
NEWTON, Mass., Oct. 3, 2017 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL) today announced that Xcede Technologies, Inc. has completed the bulk of the required ISO 10993-1 Testing Program for the Xcede Hemostatic Patch.  These studies...

16:15
SEATTLE, Oct. 3, 2017 /PRNewswire/ -- Xcede Technologies announced today that they have completed the bulk of the required ISO 10993-1 Testing Program for the Xcede Hemostatic Patch.  These studies are based on the international standard for medical...

14:41
SEATTLE, Oct. 3, 2017 /PRNewswire/ -- Sound Pharmaceuticals (SPI) is pleased to announce positive topline results from its recently completed Phase 1b SPI-1005-151 clinical trial involving Meniere's Disease (MD). SPI-1005 is an investigational new...

12:15
ANN ARBOR, Mich., Oct. 3, 2017 /PRNewswire/ -- Strata Oncology, Inc. (Strata), a precision oncology company, announced a collaboration with the University of California San Francisco (UCSF) to launch Stratify Prostatetm a unique initiative focused on...

10:12
SOUTH PLAINFIELD, N.J., Oct. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from Part 1 of the SUNFISH trial of RG7916 in Type 2/3 spinal muscular atrophy (SMA) patients.  RG7916 is part of PTC's joint development...

10:00
SAN DIEGO, October 3, 2017 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) scientists have used a standard biochemical assay to determine if some of its small molecules that have been shown to activate NR2F6 in cells,...

09:00
SALT LAKE CITY, Oct. 3, 2017 /PRNewswire/ -- DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine,...

08:53
ATLANTA, Géorgie et LAUSANNE, Suisse, October 3, 2017 /PRNewswire/ -- Il a été démontré que Triptodurtm (triptoréline), suspension injectable à libération prolongée, pouvait enrayer ou inverser l'évolution des signes cliniques de puberté associés à...

08:49
ATLANTA and LAUSANNE, Switzerland, October 3, 2017 /PRNewswire/ -- Triptodurtm, (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every...

08:30
DUBLIN, Oct. 3, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that data from new studies of VIBATIV® (telavancin) will be presented at IDWeektm 2017, being held in San Diego,...

08:30
HOUSTON, Oct. 3, 2017 /PRNewswire/ -- ImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today announced that the Company has initiated its Phase...

08:00
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, and the Stanford University School of Medicine have received a Fast-Track 1R44 Small...

08:00
ATLANTA and LAUSANNE, Switzerland, Oct. 3, 2017 /PRNewswire/ -- Arbor Pharmaceuticals, LLC, a U.S. based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm Grouptm, a Swiss-based global biopharmaceutical company,...

08:00
SAN DIEGO, Oct. 3, 2017 /PRNewswire/ --MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to...

08:00
PLEASANTON, Calif., Oct. 3, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced immediate plans to initiate screening of blood samples with the cobas® Babesia test under an Investigational New Drug Application protocol. The cobas®...

08:00
CAMBRIDGE, Mass., Oct. 3, 2017 /PRNewswire/ -- AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, today announced the initiation of patient enrollment in...

07:30
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the company recently completed enrollment of Stage 1 of its Phase 2, open-label, multi-center, two-stage study of its...

07:00
SOUTHAMPTON, England, October 3, 2017 /PRNewswire/ -- Vantia Therapeutics announces positive top-line data from a pivotal Phase III trial investigating the efficacy and safety of fedovapagon (VA106483) in the treatment of nocturia in men with benign...

1 2 3 4 5 6 7 8 9 10 11 12 13 14